Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
23 Outubro 2023 - 8:00AM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced the appointment of Eliezer Katz, M.D., FACS as Chief
Medical Officer with responsibility for leading the company’s
clinical development programs.
“We are pleased to welcome Dr. Katz to the Eledon team,” said
David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. “Dr.
Katz brings a wealth of knowledge in the surgical transplantation
field together with extensive experience designing and overseeing
clinical trials for immunosuppressive treatments. We look forward
to his leadership and contributions as we continue to advance
tegoprubart for the prevention of rejection in patients undergoing
transplantation procedures.”
Dr. Katz is an experienced transplant surgeon with significant
clinical development experience. Most recently, he was Chief
Medical Officer at eGenesis where he helped lead the clinical
development of eGenesis’ xenotransplantation programs. Prior to
eGenesis, Dr. Katz was Vice President of Clinical Development first
at Viela Bio and then at Horizon Therapeutics following its
acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led
the clinical development of inebilizumab in multiple autoimmune
indications and oversaw the regulatory submission and approval of
UPLIZNA®(inebilizumab) to treat neuromyelitis optica spectrum
disorder in adults.
Prior to Viela Bio, Dr. Katz served as Senior Director of
Clinical Development at MedImmune Inc. where he oversaw the
clinical development of three different biologics. Prior to
MedImmune, Dr. Katz served as Senior Director of Transplantation
with the Medicine Development Group at Pfizer. At Pfizer, he
oversaw multiple research programs with rapamycin, an
anti-rejection drug, and was instrumental in the regulatory
submission and FDA approval of rapamycin as a treatment for
lymphangioleiomyomatosis (LAM), a rare and fatal lung disease.
Before joining industry, Dr. Katz spent two decades as a
transplant surgeon. He was director of the abdominal
transplantation division at Integris Baptist Medical Center in
Oklahoma City, and an associate professor of surgery and the
director of the liver transplantation division at the University of
Massachusetts Medical Center, Worcester, MA. Dr. Katz spearheaded
liver transplantation advances at these institutions and was
actively involved with policy making in organ donation and
allocation. Dr. Katz earned his M.D. at Hadassah Hebrew University
Medical School in Jerusalem.
“With tegoprubart, Eledon is well positioned to meet the
critical need for innovative transplantation immunosuppressant
therapies,” said Dr. Katz. “I’m excited to join Eledon as the
company continues to realize its vision to significantly improve
the functional life of transplanted organs and address the side
effects of current immunosuppressive treatments.”
About Eledon Pharmaceuticals and
tegoprubart
Eledon Pharmaceuticals is a clinical stage biotechnology
company with immunology expertise that is developing therapies to
protect and prevent rejection of transplanted organs, as well as to
treat amyotrophic lateral sclerosis (ALS). The Company’s lead
compound in development is tegoprubart, an anti-CD40L antibody with
high affinity for CD40 Ligand, a well-validated biological target
with broad therapeutic potential. Eledon is headquartered
in Irvine, California. For more information, please visit the
company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024